Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($1.22), $0.04 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $6.43 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.